Associate Professor Simon Corrie

EXPERTISE

  • Chemical Engineering
  • Biosensors
  • BioNano engineering
  • Nanosensors
  • Engineered proteins
  • Biomaterial surfaces

Associate Professor Simon Corrie’s research interest focuses on developing nanoparticle-based molecular sensors for monitoring biological molecules in real biological environments. The Nanosensor Engineering Lab works on the design, synthesis, characterisation and testing of both synthetic nanoparticle scaffolds (e.g. organosilica materials) and novel biological reporters (e.g. antibody fragments). This requires an interdisciplinary approach, combining aspects of chemistry, and molecular biology and biomedical imaging/spectroscopy to create new materials and evaluate them in real human samples; preclinical animal studies; and/or clinical trial with the ultimate aim of translation into diagnostic products.

Associate Professor Simon Corrie completed his degree in chemical engineering and PhD in Physical Chemistry at the University of Queensland, before undertaking postdoctoral studies at the HPV Research Laboratory, University of Washington, Seattle, USA. He recently completed an ARC DECRA Fellowship in Professor Mark Kendall’s group at the Australian Institute for Bio-engineering and Nanotechnology at the University of Queensland. He is Chief Investigator in the ARC Center of Excellence in Convergent Bio-Nano Science and Technology. His research interests lie in developing nano-particles and related bio-materials for applications in bio-sensing, bio-assays and medical devices. Simon joined the Chemical Engineering Department as a Senior Lecturer in February 2016.

AMR FOCUS

  • Characterizing interactions between material surfaces (nanoparticles, medical devices) and pathogenic microbes.
  • Development of novel molecular and antigen tests for rapid sepsis diagnostics.
  • Generating rapid and high-throughput serology assays using blood-typing infrastructure already existing in hospital labs (e.g. for COVID19).

IMPACT

  • Real-time and continuous biosensing in vivo in animals and humans.
  • Rapid Detection technologies for diagnostics outside of hospital labs.
  • New nanotechnologies to detect host immune and pathogen status rapid at point of care.